Ipsos Adds Hyperlipidemia Therapy Monitor

In the US, Ipsos Healthcare has launched another in its syndicated Global Therapy Monitor series, this time covering Hyperlipidemia. Coverage will include drug share, future prescribing intentions and attributes that drive doctors' decision-making.

The Global Therapy Monitor ranges provide syndicated patient chart audit data for treatments across more than twenty disease areas. The new tool focuses specifically on hyperlipidemia patients with familial hypercholesterolemia, or a resistance to statins. According to Ipsos Healthcare, treatment of this group is currently at a 'critical stage' with the advancement of the LDL cholesterol-lowering PCSK9 inhibitor class of drugs which is currently in Phase 3 trials.

Dr Sabina Heinz, Head of the firm's Cardiovascular & Diabetes Therapy Monitor Portfolio, comments: 'Ipsos Healthcare's new monitor puts the magnifying glass onto this specific patient group, enabling pharma and biotechs to gain an understanding of market potential and current unmet needs at a time when they need it most.'

US data will be available at the beginning of first quarter 2014, with the EU5 ((France, Germany, Italy, Spain and the UK) scheduled to follow next year. The company says that given the crossover of this patient group with diabetes - another of its Therapy Monitors - subscribers will be able to see a 'holistic picture' of diabetes patients suffering from hyperlipidemia.

Web site: www.ipsos.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Ipsos UK
• All news
• MrWeb info